论文部分内容阅读
目的比较重组人组织型纤溶酶原激酶衍生物(瑞通立)与尿激酶联合低分子肝素治疗急性ST段抬高型心肌梗死的临床疗效及安全性。方法将80例急性ST段抬高型心肌梗死随机分为治疗组和对照组,其中治疗组40例,给予瑞通立以及低分子肝素;对照组40例,给予尿激酶和低分子肝素。观察并比较两组患者的血管再通率、出血并发症、心律失常发生率、急性期病死率等。结果治疗组血管再通率明显高于对照组,差异有统计学意义(P<0.05);治疗组并发症、心律失常发生率明显低于对照组,差异有统计学意义(P<0.05);而两组患者急性期病死率比较差异未见统计学意义(P>0.05)。结论相对于尿激酶,瑞通立联合低分子肝素能更有效的开通闭塞血管,且安全性较好,并发症较低。
Objective To compare the clinical efficacy and safety of recombinant human tissue plasminogen kinase (Ruitongli) and urokinase combined with low molecular weight heparin in the treatment of acute ST-segment elevation myocardial infarction. Methods Eighty patients with acute ST-elevation myocardial infarction were randomly divided into treatment group and control group. Forty patients in the treatment group were treated with Ruitongli and low molecular weight heparin. The control group, 40 patients, were given urokinase and low molecular weight heparin. The vascular recanalization rate, bleeding complications, arrhythmia incidence and acute stage mortality were observed and compared between the two groups. Results The rate of vascular recanalization in the treatment group was significantly higher than that in the control group (P <0.05). The incidence of complications and arrhythmia in the treatment group was significantly lower than that in the control group (P <0.05). However, there was no significant difference in mortality rate between two groups in acute stage (P> 0.05). Conclusion Compared with urokinase, Ruitongli combined with low molecular weight heparin can effectively open the occluded blood vessels with better safety and lower complication rate.